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Summary of the research
Recent evidence demonstrated the ability of some antifungals to induce (re)myelination in specic 
experimental models. These compounds, already marketed for dierent pathologies, are interesting 
candidates for a repurposing strategy in neurodegenerative diseases, like multiple sclerosis (MS), 
characterized by strong demyelination.  Our preliminary results show that the inhibition of enzymes 
involved in retinoic acid (RA) catabolism (CYP26), by miconazole and other azole antifungals, induces an 
increase of cellular RA concentration and that this increase may be behind the observed oligodendrocyte 
precursor cell (OPC) maturation and dierentiation. On this basis, our proposal is aimed at studying the 
molecular mechanisms of azole antifungals used in human pharmacology, both in silico and in vitro, and at 
identifying the most promising ones according to their ability to increase Myelin Basic Protein (MBP) 
expression on OPCs and to promote their dierentiation and myelination.
In our investigation, the ability of 7 azoles to inhibit CYP26 isozymes was evaluated through molecular 
docking: in silico results were the basis for the selection of the drugs for the in vitro experiments. The selected 
azoles were tested in three dierent cell models, characterized by increasing complexity: i) OPC cultures, a 
maturation assay for myelin-producing cells; ii) OPC-dorsal root ganglion (DRG) neuron co-cultures, a 
myelination assay; iii) cerebral micromass cultures, a cell dierentiation assay for CNS.
In parallel, the eects of exogenous RA and of an inhibitor of the synthesis of RA (citral), were evaluated as 
well. In the next phase of the project, the outcomes from the dierent in vitro models will be statistically 
correlated with the pharmacological treatments. 
Our results will be useful: 1) for identifying the most promising azole antifungals with respect to their 
pro-myelinating activity, 2) for clarifying the molecular mechanisms underlying their reparative eect and 3) 
for formalizing mathematical models to identify the most active concentrations for the most potent azoles. 
Since no crystal structure is yet available for 
any member of the CYP26 family, models of 
the 3D structures of the three isoenzymes 
(CYP26A1, CYP26B1 and CYP26C1) were 
built for both the human and the rat protein 
via comparative modelling, using the X-ray 
structure of the RA-bound cyanobacterial 
CYP120A1 cytochrome as template 
(sequence identity approx. 34% for all the 
queries). 
Then, in silico RA::CYP26s 3D complexes 
were optimized for further computations 
and nally relaxed via energy minimization 
(EM). 
All the in silico procedures were carried out 
with the MOE Suite 2016.08.
In silico evaluation of azole anity for CYP26 isoenzymes
Seven dierent azoles in clinical use for human pathologies were selected and their propensity to inhibit 
both the human and rat Cyp26 isoenzymes was investigated in silico through molecular docking. RA, which is 
known to be catabolized by CYP26 in humans (Menegola et al. 2006), was included in this procedure as 
control. All the generated complexes were carefully inspected: as already reported for CYP450 (Li et al. 2012), 
also in CYP26 the nitrogen atom of the azole ring coordinates the heme iron and the compounds occupy the 
binding pocket blocking the access of the substrate to the catalytic site.  Accurate binding free energy values 
(anity) were computed by rening the docking complexes, relaxing the ligand within the binding pocket 
and applying a constrained forceeld EM. In silico dissociation constants (Ki) were estimated on the basis of 
their binding free energy values to prioritize azoles and to set-up in vitro experiments.
According to computed Ki, itraconazole and posaconazole were selected as the most promising compounds 
to be forwarded to the in vitro test. In parallel, the eect of uconazole, which has the lowest anity for the 
CYP26 family, was also evaluated. Predicted Ki values for miconazole are consistent with literature data (Najm 
et al. 2015).
Eect of antifungal azoles on OPC maturation assay
Treatment of in vitro OPC cultures with RA (50 nM, A) is able to increase the number of  MBP+-expressing 
cells, whereas the treatment with citral (150 uM, B) produces a decrease in the number of MBP+ cells 
versus vehicle-treated cells (C). When RA and citral are administered in combination to OPCs (D), the eect 
of RA is reduced. Also the selected azoles (E-G), when administered to OPCs at selected concentrations 
(1-30 nM), signicantly increase the number of MBP+ cells versus control.
Eect of antifungal azoles on OPC-DRG myelination assay
OPC cultured on DRG neurons were exposed to itraconazole (10 nM) and uconazole (30 nM). Both azoles 
(A, B), similarly to RA (50 nM, C), were able to signicantly increase the formation of double positive 
MBP/NF-myelinated axons versus vehicle-treated cultures (D). Also in this case, when azoles or RA were 
administered to OPC-DRG cultures in combination with the RA inhibitor citral (150 uM, E-G), the eect on 
myelination was reduced with respect to the same compound alone.
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Next steps
Further treatments on cerebral micromass cultures with the selected azoles either alone or in combination 
with the RA ihibitor citral are currently ongoing. The micrographs show the images of untreated rat cerebral 
micromass, after 2 day in culture (A) and stained with methylen blue (B) and hematoxylin (C).
As soon as the analysis will be completed, all the in silico and in vitro results produced within this project 
will be comprehensively integrated via statistical and numerical analysis. The elucidation of the role of 
azoles in RA-mediated (re)myelination will provide the basis for the identication of new promising 
candidates for repurposing strategies in MS.
Conclusions
Overall, these results demonstrate that antifungal azoles are able to increase MBP expression and the 
formation of myelinating bers on both OPC and OPC-DRG in vitro cultures, as already demonstrated for 
miconazole (Najm et al. 2015). These data suggest that the pro-myelinating eect of antifungal azoles may be 
connected with the increased local bioavailability of RA.
Azoles 
on rat 
CYP26s 
Binding 
free energy 
(kcal/mol) 
Anity 
(kcal/mol) 
Ki 
CYP26 
Isoenzyme 
Itraconazole -11.2 -12.1 8.9 CYP26A1 
Posaconazole -9.7 -10.8 7.9 CYP26A1 
Ketoconazole -9.4 -13.7 10.1 CYP26A1 
Isavuconazole -8.5 -9.8 7.2 CYP26A1 
Retinoic Acid -8.3 -8.6 6.3 CYP26A1 
Miconazole -8.0 -8.6 6.3 CYP26A1 
Voriconazole -7.1 -8.4 6.2 CYP26C1 
Fluconazole -7.0 -7.1 5.2 CYP26C1 
!
 
 
Azoles 
on human 
CYP26s 
Binding 
free energy 
(kcal/mol) 
Anity 
(kcal/mol) 
Ki 
CYP26 
Isoenzyme 
Itraconazole -11.8 -13.4 9.9 CYP26B1 
Posaconazole -11.1 -13.3 9.8 CYP26B1 
Ketoconazole -9.9 -12.3 9.1 CYP26B1 
Isavuconazole -9.3 -9.6 7.1 CYP26A1 
Retinoic Acid -8.3 -8.5 6.3 CYP26C1 
Miconazole -8.2 -8.7 6.4 CYP26A1 
Voriconazole -7.6 -13.4 9.9 CYP26B1 
Fluconazole -7.0 -7.6 5.6 CYP26A1 
 
 
 
 
 
Itraconazole  binding pose for Human CYP26A1
No dierences in anity for the investigated azoles 
was found between human and rat CYP26s, 
suggesting that rat OPC cultures are a suitable model 
for testing clinically used azoles.
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Molecular modeling for CYP26 isoenzymes
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